| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 05/09/2022 | 131.24% | JMP Securities | $165 → $110 | Maintains | Market Outperform |
| 05/06/2022 | 106.01% | Credit Suisse | $100 → $98 | Maintains | Outperform |
| 05/06/2022 | 120.73% | Raymond James | $181 → $105 | Maintains | Outperform |
| 04/28/2022 | 110.22% | Credit Suisse | → $100 | Initiates Coverage On | → Outperform |
| 03/07/2022 | 91.3% | Brookline Capital | → $91 | Upgrades | Hold → Buy |
| 03/01/2022 | 261.57% | Chardan Capital | $177 → $172 | Maintains | Buy |
| 02/18/2022 | — | William Blair | Initiates Coverage On | → Outperform | |
| 02/14/2022 | — | Brookline Capital | Initiates Coverage On | → Hold | |
| 02/07/2022 | 215.32% | Oppenheimer | $145 → $150 | Upgrades | Perform → Outperform |
| 01/31/2022 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 01/07/2022 | 246.86% | JMP Securities | $175 → $165 | Maintains | Market Outperform |
| 01/07/2022 | 259.47% | Piper Sandler | → $171 | Initiates Coverage On | → Overweight |
| 11/05/2021 | 204.81% | Oppenheimer | $160 → $145 | Maintains | Perform |
| 11/05/2021 | 282.59% | HC Wainwright & Co. | $171 → $182 | Maintains | Buy |
| 10/05/2021 | 257.37% | Guggenheim | → $170 | Initiates Coverage On | → Buy |
| 09/24/2021 | 263.67% | Stifel | → $173 | Initiates Coverage On | → Buy |
| 08/06/2021 | 280.49% | Raymond James | $168 → $181 | Maintains | Outperform |
| 08/06/2021 | 267.88% | JMP Securities | $160 → $175 | Maintains | Market Outperform |
| 08/06/2021 | 236.35% | Oppenheimer | $125 → $160 | Maintains | Perform |
| 08/06/2021 | 429.75% | Goldman Sachs | $225 → $252 | Maintains | Buy |
| 08/06/2021 | 272.08% | Chardan Capital | $130 → $177 | Maintains | Buy |
| 06/29/2021 | 162.77% | Oppenheimer | $73 → $125 | Maintains | Perform |
| 06/29/2021 | 253.16% | Raymond James | $106 → $168 | Maintains | Outperform |
| 06/28/2021 | 82.89% | Wedbush | $73 → $87 | Maintains | Neutral |
| 06/28/2021 | 181.69% | Barclays | $88 → $134 | Maintains | Overweight |
| 06/28/2021 | 242.65% | Goldman Sachs | $115 → $163 | Maintains | Buy |
| 06/28/2021 | 236.35% | Truist Securities | $80 → $160 | Maintains | Buy |
| 06/28/2021 | 131.24% | Roth Capital | $80 → $110 | Maintains | Buy |
| 06/28/2021 | 259.47% | HC Wainwright & Co. | $111 → $171 | Maintains | Buy |
| 06/28/2021 | 173.28% | Chardan Capital | $85 → $130 | Maintains | Buy |
| 06/23/2021 | 84.99% | JMP Securities | $80 → $88 | Maintains | Market Outperform |
| 06/23/2021 | 78.68% | Baird | $60 → $85 | Maintains | Neutral |
| 06/11/2021 | 133.34% | HC Wainwright & Co. | → $111 | Initiates Coverage On | → Buy |
| 05/07/2021 | 68.17% | Roth Capital | $75 → $80 | Upgrades | Neutral → Buy |
| 05/04/2021 | 131.24% | RBC Capital | → $110 | Initiates Coverage On | → Outperform |
| 03/04/2021 | 68.17% | JMP Securities | → $80 | Initiates Coverage On | → Outperform |
| 02/10/2021 | 78.68% | Chardan Capital | $57.5 → $85 | Maintains | Buy |
| 01/08/2021 | 122.83% | Raymond James | $39 → $106 | Maintains | Outperform |
| 12/22/2020 | — | Baird | Downgrades | Outperform → Neutral | |
| 10/27/2020 | -15.91% | Truist Securities | → $40 | Initiates Coverage On | → Buy |
| 10/14/2020 | — | Wells Fargo | Initiates Coverage On | → Overweight | |
| 09/18/2020 | -30.63% | Goldman Sachs | → $33 | Initiates Coverage On | → Buy |
| 06/02/2020 | -55.85% | Credit Suisse | $19 → $21 | Maintains | Neutral |
| 02/28/2020 | — | Oppenheimer | Upgrades | Perform → Outperform | |
| 02/14/2020 | -66.37% | Wedbush | $21 → $16 | Downgrades | Outperform → Neutral |
| 11/01/2019 | -49.55% | Raymond James | → $24 | Upgrades | Market Perform → Outperform |
| 07/09/2019 | -51.65% | Baird | → $23 | Initiates Coverage On | → Outperform |
| 06/10/2019 | -66.37% | Roth Capital | → $16 | Initiates Coverage On | → Neutral |
| 05/03/2019 | — | Wedbush | Upgrades | Neutral → Outperform | |
| 05/03/2019 | — | Wedbush | Upgrades | Neutral → Outperform | |
| 04/12/2019 | — | Evercore ISI Group | Initiates Coverage On | → Outperform | |
| 02/08/2019 | -57.96% | BTIG | → $20 | Initiates Coverage On | → Buy |
| 11/28/2018 | -51.65% | Leerink Swann | → $23 | Initiates Coverage On | → Outperform |
| 11/02/2018 | -57.96% | Wedbush | $36 → $20 | Downgrades | Outperform → Neutral |
| 09/21/2018 | — | Raymond James | Initiates Coverage On | → Market Perform | |
| 05/15/2018 | — | Chardan Capital | Upgrades | Neutral → Buy | |
| 03/08/2018 | 59.76% | JMP Securities | → $76 | Initiates Coverage On | → Market Outperform |
| 03/07/2018 | -3.3% | Barclays | $33 → $46 | Maintains | Overweight |
| 11/03/2017 | -41.14% | Credit Suisse | $24 → $28 | Maintains | Outperform |
| 11/01/2017 | -11.71% | Jefferies | $36 → $42 | Maintains | Buy |
| 09/07/2017 | -39.04% | Barclays | → $29 | Initiates Coverage On | → Overweight |
| 08/29/2017 | — | Chardan Capital | Downgrades | Buy → Neutral | |
| 08/02/2017 | -57.96% | Chardan Capital | $19 → $20 | Maintains | Buy |
| 07/18/2017 | — | Oppenheimer | Initiates Coverage On | → Perform |
Intellia Therapeutics Questions & Answers
The latest price target for Intellia Therapeutics (NASDAQ: NTLA) was reported by Credit Suisse on May 6, 2022. The analyst firm set a price target for $98.00 expecting NTLA to rise to within 12 months (a possible 106.01% upside). 32 analyst firms have reported ratings in the last year.
The latest analyst rating for Intellia Therapeutics (NASDAQ: NTLA) was provided by Credit Suisse, and Intellia Therapeutics maintained their outperform rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Intellia Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Intellia Therapeutics was filed on May 6, 2022 so you should expect the next rating to be made available sometime around May 6, 2023.
While ratings are subjective and will change, the latest Intellia Therapeutics (NTLA) rating was a maintained with a price target of $100.00 to $98.00. The current price Intellia Therapeutics (NTLA) is trading at is $47.57, which is out of the analyst's predicted range.